期刊文献+

表皮生长因子受体在前列腺癌雄激素非依赖型细胞系中表达的意义 被引量:2

Epidermal growth factor receptor expression in human prostate androgen unresponsive cancer cells
原文传递
导出
摘要 目的 探讨转化生长因子 (TGF) α和表皮生长因子 (EGF)对前列腺癌雄激素非依赖型细胞系中表皮生长因子受体 (EGFR)表达的调控作用。方法 采用逆转录 多聚酶链式反应和免疫印迹法分别对TGF α和EGF刺激前列腺癌雄激素非依赖型细胞系PC3、ARCaP后EGFRmRNA表达及其蛋白水平进行定量分析。结果 EGF引起PC3、ARCaP的EGFRmRNA升高 ,分别为5.0 1± 0 .45和 2 .41± 0 .2 6,差异无显著性 (P >0 .0 5) ;TGF α引起各细胞系EGFRmRNA升高 ,分别为 9.0 5± 0 .63和 3 .54± 0 .3 3 ,差异无显著性 (P >0 .0 5)。各细胞系EGFR蛋白水平TGF α组明显高于EGF组 (P <0 .0 5)。结论 TGF/EGF EGFR通路在发生发展中起重要作用 ;TGFα EGFR自分泌环在非依赖型前列腺癌中的作用强于EGF EGFR自分泌环。 Objective To elucidate the regulation of epidermal growth factor receptor (EGFR) expression by transforming growth factor (TGF) α and epidermal growth factor (EGF) in human prostate androgen unresponsive cancer cells.Methods EGFR mRNA expression and its protein level were measured by means of RT PCR and Western blot respectively in human prostate cancer androgen unresponsive cell lines, ARCaP and PC3, all treated with exogenous EGF or TGF a.Results In TGFa treated groups the levels of EGFR mRNA were 5.01±0.45 and 2.41±0.26 in PC3 and ARCaP respectively (P>0.05), while in the EGF treated groups the levels of EGFR mRNA were 9.05±0.63 and 3.54±0.33 in them respectively (P>0.05). In all cell lines TGF a induced total EGFR protein levels higher than EGF (P<0.05).Conclusion TGF α/EGF EGFR path way serves as a key growth regulator in prostate cancer.TGF α, but not EGF, would preferentially maintain an autocrine loop in human androgen unresponsive prostate cancer.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2001年第5期422-423,共2页 Chinese Journal of Experimental Surgery
基金 江苏省自然科学基金资助项目 (BK991 5 1 )
关键词 前列腺肿瘤 表皮生长因子受体 自身分泌活动因子 TGFΑ EGF Prostatic neoplasms Epidermal growth factor receptor Autocrine motidity factor
  • 相关文献

参考文献6

  • 1Seth D,Shaw K,Jazayeri J,et al.Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-αin human prostate cancer cell[].British Journal of Cancer.1999
  • 2Dahiya R,Lee C,Haughney PC,et al.Differential gene expression of transforming growth factors alpha and beta, epidermal growth factor,kerationocyte growth factor, and their receptors in fetal and docult human prostatic tissues and cancer cell lines[].Urology.1996
  • 3Leow I,McNeal JE,Ziar J,et al.The localization of transforming growth factor alpha and epidermal growth factor receptor in stromal and epithelial compartment of developing human prostate and hyperplastic, dysplastic, and carcinomatous lesions[].Human Pathology.1998
  • 4Glynne JE,Goddard Z,Harper ME,et al.Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue[].Human Pathology.1996
  • 5Waterman H,Sabanai L,Geiger B,et al.Alternative intracellular routing of erb-B receptors may determine signaling potency[].Journal of Biological Chemistry.1998
  • 6Byrne RL,Leung H,Neal DE.Peptide grouth factors in the prostate as mediators of stromal epithelial interaction[].British Journal of Urology.1996

同被引文献12

  • 1王小林,侯建全,温端改,何军,岑建农,谷敏.利用RNA干扰阻抑膀胱癌细胞Survivin基因表达和诱导凋亡[J].中华实验外科杂志,2006,23(10):1174-1176. 被引量:12
  • 2Metro G, Finocchiaro G, Toschi L, et al. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC) [ J ]. Rev Recent Clin Trials, 2006, 1 (1):1-13.
  • 3Small E J, Fontana J, Tannir N, et al. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer[J]. BJU Int, 2007, 100(4) :765-769.
  • 4Boccardo F, Rubagotti A, Conti G, et al. Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial [J]. Oneology, 2008, 74(3-4):223-228.
  • 5Ferrer-Soler L, Vazquez-Mmtin A, Brunet J, et al. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands[J]. IntJ Mol Med, 2007, 20(1):3-10.
  • 6Han S W, Hwang P G, Chung D H, et al. Epidermal growth favor receptor(DGFR) downstream molecules as response predictive markers for gefitinib (Gefifinib ZD1839) in chemotherapy-resistant nonsmall cell lung cancer [ J]. Int J Cancer, 2005, 113(1) : 109-115.
  • 7Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor(EGFR) signaling in cancer[J]. Gene, 2006, 366(1) :2-16.
  • 8Cappuzzo F, Magrini E, Ceresoli G L, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-smallcell lung cancer[J]. J Natl Cancer Inst, 2004, 96(15) :1133- 1141.
  • 9Balsara B R, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions [ J ]. Carcinogenesis, 2004, 25 ( 11 ) : 2053- 2059.
  • 10Kumartm A, Petri E T, Halmos B, et al. Structure and clinical relevance of the epidemal growth factor receptor in human cancer[J]. J Clin Oncol, 2008, 26(10):1742-1751.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部